Irritable Bowel Syndrome Treatment Market is Expected to Experience a Swift Development

1
Title Irritable Bowel Syndrome (IBS) Treatment
Market Summery Irritable Bowel Syndrome (IBS)
Treatment Market Forecast to 2028 - COVID-19
Impact and Global Analysis By Type IBS with
Diarrhea (IBS-D), IBS with Constipation (IBS-C),
and Mixed IBS (IBS-M), Product (Rifaximin,
Eluxadoline, Lubiprostone, Linaclotide, and
Others), and Distribution Channel (Hospital
Pharmacies, Drug Stores and Retail Pharmacies,
and Online Pharmacies) Description The
irritable bowel syndrome (IBS) treatment market
was valued at US 2,153.89 million in 2020 and
is projected to reach US 4,600.30 million by
2028 it is expected to grow at a CAGR of 10.1
from 2021 to 2028.
The growth of the irritable bowel syndrome (IBS)
treatment market is primarily attributed to the
key driving factors such as increasing IBS
diseases prevalence and rising research
development activities. However, the limited
number of product availability and treatment
inefficiency hinder the market growth. Ironwood
Pharmaceuticals, Inc. AbbVie. Sebela
Pharmaceuticals, Inc. Takeda Pharmaceutical
Company Limited Alfasigma S.p.A. Astellas
Pharma Inc. AstraZeneca Synthetic Biologics,
Inc. Bausch Lomb Incorporated and Lannett
Company Inc are among the leading companies
operating in the market.
Get Sample PDF
https//www.theinsightpartners.com/sample/TIPRE000
06814/ Based on type, the irritable bowel
syndrome (IBS) treatment market is segmented into
mixed IBS (IBS-M), IBS with diarrhea (IBS-D),
and IBS with constipation (IBS-C). The mixed IBS
(IBS-M) segment held the largest share of the
market in 2020. Also, the same segment is
expected to register the highest CAGR during
20212028. In the coming years, the rising
prevalence of IBS among women and men is
anticipated to propel the demand for the
medicines that can treat combined symptoms of
constipation and diarrhea. According to updated
Rome IV criteria, the reverse condition of IBS-M
is described as a model of hard or irregular
stools in more than 25 of bowel movements. The
prevalence is higher in the geriatric population.
Therefore, the demand for medicines to treat
mixed IBS is likely to grow significantly during
the forecast period,
Buy Now https//www.theinsightpartners.com/buy/TI
PRE00006814/
The report segments global irritable bowel
syndrome (IBS) treatment market as Follows
2
By Type By Type By Type By Type By Type
IBS with Diarrhea (IBS-D) IBS with Constipation (IBS-C) Mixed IBS (IBS-M) IBS with Diarrhea (IBS-D) IBS with Constipation (IBS-C) Mixed IBS (IBS-M) IBS with Diarrhea (IBS-D) IBS with Constipation (IBS-C) Mixed IBS (IBS-M) IBS with Diarrhea (IBS-D) IBS with Constipation (IBS-C) Mixed IBS (IBS-M)
By Product By Product By Product By Product By Product
Rifaximin Eluxadoline Linaclotide Lubiprostone Others Rifaximin Eluxadoline Linaclotide Lubiprostone Others Rifaximin Eluxadoline Linaclotide Lubiprostone Others Rifaximin Eluxadoline Linaclotide Lubiprostone Others
By Distribution Channel By Distribution Channel By Distribution Channel By Distribution Channel By Distribution Channel
Hospitals Pharmacies Drug Stores and Retail Pharmacies Online Pharmacies Hospitals Pharmacies Drug Stores and Retail Pharmacies Online Pharmacies Hospitals Pharmacies Drug Stores and Retail Pharmacies Online Pharmacies Hospitals Pharmacies Drug Stores and Retail Pharmacies Online Pharmacies
By Geography By Geography By Geography By Geography By Geography
North America North America North America
o o
US Canada Mexico
Europe Europe Europe
o o
France Germany UK Spain Italy Rest of Europe

• Asia Pacific (APAC)

• o
• China
• India
• Japan
• Australia
• South Korea

3

• Rest of APAC

• Middle East and Africa (MEA)

• o
• Saudi Arabia
• UAE
• South Africa
• Rest of MEA
• South and Central America (SCAM)

o

• Brazil
• Argentina
• Rest of SCAM

• Company Profiles
• Ironwood Pharmaceuticals, Inc.
• AbbVie.
• Sebela Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Alfasigma S.p.A.
• Astellas Pharma Inc.
• AstraZeneca
• Synthetic Biologics, Inc.
• Bausch Lomb Incorporated
• Lannett Company Inc
• About Us
• The Insight Partners is a one stop industry
  research provider of actionable intelligence. We
  help our
• clients in getting solutions to their research
  requirements through our syndicated and
  consulting research services. We specialize in
  industries such as Semiconductor and Electronics,
  Aerospace and
• Defense, Automotive and Transportation,
  Biotechnology, Healthcare IT, Manufacturing and
  Construction, Medical Device, Technology, Media
  and Telecommunications, Chemicals and Materials.
• Contact Us
• If you have any queries about this report or if
  you would like further information, please
  contact us Contact Person Sameer Joshi

4
(No Transcript)